Pluristem Therapeutics, Inc. (PSTI) Receives Buy Rating from HC Wainwright
Pluristem Therapeutics, Inc. (NASDAQ:PSTI)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday. They presently have a $3.50 price objective on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 146.48% from the company’s current price.
PSTI has been the subject of several other reports. Maxim Group upgraded Pluristem Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Monday, June 19th. ValuEngine lowered Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $3.19.
Pluristem Therapeutics (NASDAQ PSTI) traded up 1.056% during mid-day trading on Tuesday, hitting $1.435. 861,200 shares of the company traded hands. The company’s 50-day moving average price is $1.19 and its 200 day moving average price is $1.28. Pluristem Therapeutics has a one year low of $1.04 and a one year high of $1.66. The company’s market capitalization is $139.87 million.
A hedge fund recently raised its stake in Pluristem Therapeutics stock. Jane Street Group LLC lifted its holdings in Pluristem Therapeutics, Inc. (NASDAQ:PSTI) by 62.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 108,830 shares of the biotechnology company’s stock after purchasing an additional 41,796 shares during the quarter. Jane Street Group LLC owned about 0.11% of Pluristem Therapeutics worth $134,000 as of its most recent SEC filing. Institutional investors and hedge funds own 4.47% of the company’s stock.
About Pluristem Therapeutics
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.